NCI-H28Homo sapiens (Human)Cancer cell line

Also known as: HuT28, Hut28, HUT28, HuT 28, HUT 28, HUT-28, NCIH28, H-28, H28

🤖 AI SummaryBased on 15 publications

Quick Overview

Malignant mesothelioma cell line with known genetic alterations

Detailed Summary

The NCI-H28 cell line is a malignant mesothelioma cell line derived from human tissue. It is characterized by specific genetic alterations, including mutations in the BAP1 gene and other key tumor suppressor genes. This cell line is used in research to study the molecular mechanisms of mesothelioma, particularly focusing on the Hippo signaling pathway and its role in tumor progression. The cell line has been utilized in studies investigating the effects of gene mutations on cell proliferation, apoptosis, and drug sensitivity. Research involving NCI-H28 has contributed to understanding the genetic basis of mesothelioma and has implications for developing targeted therapies.

Research Applications

Study of genetic alterations in mesotheliomaInvestigation of the Hippo signaling pathwayAnalysis of tumor suppressor gene mutationsDrug sensitivity and resistance studies

Key Characteristics

BAP1 gene mutationsHippo pathway involvementTumor suppressor gene inactivation
Generated on 6/17/2025

Basic Information

Database IDCVCL_1555
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age48
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseasePleural mesothelioma
LineagePleura
SubtypePleural Mesothelioma, Epithelioid Type
OncoTree CodePLEMESO

DepMap Information

Source TypeATCC
Source IDACH-000648_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleVHLp.Leu89His (c.266T>A)Unspecified-PubMed=7915601
MutationNone reportedTP53---PubMed=19787792
MutationSimpleBAP1p.Arg146Alafs*48 (c.438-24_438-2del23)Homozygous-PubMed=26011428, PubMed=21642991
Gene deletionCTNNB1-Homozygous-PubMed=11464291, PubMed=11070089
Gene deletionCDKN2A-HomozygousPossiblePubMed=26870271

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
10,11
D13S317
11,13
D16S539
12,13
D18S51
19
D19S433
12,14.2
D21S11
29,30
D2S1338
18,22
D3S1358
17
D5S818
11
D7S820
10,12
D8S1179
10,12
FGA
19.2,21
Penta D
9,10
Penta E
10,16
TH01
7,9
TPOX
11
vWA
14,15
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in merlin-negative malignant mesothelioma cells.

Kato T., Sato T., Yokoi K., Sekido Y.

Oncogene 36:5522-5531(2017).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells.

Yokoi K., Sekido Y.

Cancer Sci. 106:990-999(2015).

Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.

Asamura H., Gemma A., Yamada T.

J. Thorac. Oncol. 10:844-851(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.

Rice D.C., Tsao A., Wistuba I.I.

J. Thorac. Oncol. 9:998-1007(2014).

Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.

Meltzer P.S., Kirsch I.R., Kaye F.J., Roschke A.V.

Cancer Genet. 206:191-205(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Powell S.N., Zhou Q., Shen R.-L., Olshen A.B., Rusch V.W., Ladanyi M.

Nat. Genet. 43:668-672(2011).

LATS2 is a tumor suppressor gene of malignant mesothelioma.";

Sekido Y.

Cancer Res. 71:873-883(2011).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32.

Sekido Y.

Cancer Sci. 98:438-446(2007).

Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.

Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T.

Cancer Sci. 97:387-394(2006).

Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion.

Yoshioka H., Imaizumi M., Ueda Y., Takahashi M., Shimokata K.

Oncogene 20:4249-4257(2001).

Altered HOX and WNT7A expression in human lung cancer.";

Gemmill R.M., Drabkin H.A.

Proc. Natl. Acad. Sci. U.S.A. 97:12776-12781(2000).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines.

Zbar B., Lerman M.I., Minna J.D.

Oncogene 9:1599-1604(1994).

High levels of intracellular bombesin characterize human small-cell lung carcinoma.

Moody T.W., Pert C.B., Gazdar A.F., Carney D.N., Minna J.D.

Science 214:1246-1248(1981).

p53 and Kirsten-ras mutations in human mesothelioma cell lines.";

Harris C.C.

Cancer Res. 52:2610-2615(1992).

Web Resources